Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia

Charles DeCarli, Giovanni B. Frisoni, Christopher M. Clark, Danielle Harvey, Michael Grundman, Ronald C. Petersen, Leon J. Thal, Shelia Jin, Clifford R. Jack, Philip Scheltens

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Background: Individuals diagnosed as having mild cognitive impairment (MCI) have a high likelihood of progressing to dementia within 3 to 5 years, but not all individuals with MCI progress to dementia. Prognostic uncertainty suggests the need for additional measures to assist the clinician. Objective: To assess the added value of qualitative measures of medial temporal atrophy (MTA) to estimate the relative risk of progressing from MCI to dementia. Design: A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia. Setting: Memory assessment centers. Patients: A total of 190 individuals with MCI. Main Outcome Measures: Ratings of MTA performed using magnetic resonance images obtained at baseline. Log-rank tests and Cox proportional hazards ratios examining the significance of MTA estimates in predicting progression of MCI to dementia. Results: A mean MTA score greater than 2.0 was associated with a greater than 2-fold increased likelihood of progression to dementia during the observation period (hazards ratio, 2.30; 95% confidence interval, 1.09-4.92; P=.03) after controlling for age, education, sex, and baseline Mini-Mental State Examination score. Conclusions: Adjusted estimates of MTA were associated with significantly increased risk of developing dementia within 3 years, suggesting that obtaining a magnetic resonance image during the evaluation of MCI may offer additional independent information about the risk of progression to dementia. Given the relatively high prevalence of MCI in the general population, use of this method as part of routine clinical evaluation may help identify individuals who might benefit from increased surveillance and future treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00000173.

Original languageEnglish
Pages (from-to)108-115
Number of pages8
JournalArchives of Neurology
Volume64
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Atrophy
Dementia
Magnetic Resonance Spectroscopy
Placebos
Sex Education
Cognitive Dysfunction
Mild Cognitive Impairment
Progression
Predictors
Vitamin E
Uncertainty
Alzheimer Disease
Observation
Outcome Assessment (Health Care)
Confidence Intervals
Population

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. / DeCarli, Charles; Frisoni, Giovanni B.; Clark, Christopher M.; Harvey, Danielle; Grundman, Michael; Petersen, Ronald C.; Thal, Leon J.; Jin, Shelia; Jack, Clifford R.; Scheltens, Philip.

In: Archives of Neurology, Vol. 64, No. 1, 01.2007, p. 108-115.

Research output: Contribution to journalArticle

DeCarli, C, Frisoni, GB, Clark, CM, Harvey, D, Grundman, M, Petersen, RC, Thal, LJ, Jin, S, Jack, CR & Scheltens, P 2007, 'Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia', Archives of Neurology, vol. 64, no. 1, pp. 108-115. https://doi.org/10.1001/archneur.64.1.108
DeCarli, Charles ; Frisoni, Giovanni B. ; Clark, Christopher M. ; Harvey, Danielle ; Grundman, Michael ; Petersen, Ronald C. ; Thal, Leon J. ; Jin, Shelia ; Jack, Clifford R. ; Scheltens, Philip. / Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. In: Archives of Neurology. 2007 ; Vol. 64, No. 1. pp. 108-115.
@article{d7eaace4f50f49f0815f60da1798eb30,
title = "Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia",
abstract = "Background: Individuals diagnosed as having mild cognitive impairment (MCI) have a high likelihood of progressing to dementia within 3 to 5 years, but not all individuals with MCI progress to dementia. Prognostic uncertainty suggests the need for additional measures to assist the clinician. Objective: To assess the added value of qualitative measures of medial temporal atrophy (MTA) to estimate the relative risk of progressing from MCI to dementia. Design: A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia. Setting: Memory assessment centers. Patients: A total of 190 individuals with MCI. Main Outcome Measures: Ratings of MTA performed using magnetic resonance images obtained at baseline. Log-rank tests and Cox proportional hazards ratios examining the significance of MTA estimates in predicting progression of MCI to dementia. Results: A mean MTA score greater than 2.0 was associated with a greater than 2-fold increased likelihood of progression to dementia during the observation period (hazards ratio, 2.30; 95{\%} confidence interval, 1.09-4.92; P=.03) after controlling for age, education, sex, and baseline Mini-Mental State Examination score. Conclusions: Adjusted estimates of MTA were associated with significantly increased risk of developing dementia within 3 years, suggesting that obtaining a magnetic resonance image during the evaluation of MCI may offer additional independent information about the risk of progression to dementia. Given the relatively high prevalence of MCI in the general population, use of this method as part of routine clinical evaluation may help identify individuals who might benefit from increased surveillance and future treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00000173.",
author = "Charles DeCarli and Frisoni, {Giovanni B.} and Clark, {Christopher M.} and Danielle Harvey and Michael Grundman and Petersen, {Ronald C.} and Thal, {Leon J.} and Shelia Jin and Jack, {Clifford R.} and Philip Scheltens",
year = "2007",
month = "1",
doi = "10.1001/archneur.64.1.108",
language = "English",
volume = "64",
pages = "108--115",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia

AU - DeCarli, Charles

AU - Frisoni, Giovanni B.

AU - Clark, Christopher M.

AU - Harvey, Danielle

AU - Grundman, Michael

AU - Petersen, Ronald C.

AU - Thal, Leon J.

AU - Jin, Shelia

AU - Jack, Clifford R.

AU - Scheltens, Philip

PY - 2007/1

Y1 - 2007/1

N2 - Background: Individuals diagnosed as having mild cognitive impairment (MCI) have a high likelihood of progressing to dementia within 3 to 5 years, but not all individuals with MCI progress to dementia. Prognostic uncertainty suggests the need for additional measures to assist the clinician. Objective: To assess the added value of qualitative measures of medial temporal atrophy (MTA) to estimate the relative risk of progressing from MCI to dementia. Design: A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia. Setting: Memory assessment centers. Patients: A total of 190 individuals with MCI. Main Outcome Measures: Ratings of MTA performed using magnetic resonance images obtained at baseline. Log-rank tests and Cox proportional hazards ratios examining the significance of MTA estimates in predicting progression of MCI to dementia. Results: A mean MTA score greater than 2.0 was associated with a greater than 2-fold increased likelihood of progression to dementia during the observation period (hazards ratio, 2.30; 95% confidence interval, 1.09-4.92; P=.03) after controlling for age, education, sex, and baseline Mini-Mental State Examination score. Conclusions: Adjusted estimates of MTA were associated with significantly increased risk of developing dementia within 3 years, suggesting that obtaining a magnetic resonance image during the evaluation of MCI may offer additional independent information about the risk of progression to dementia. Given the relatively high prevalence of MCI in the general population, use of this method as part of routine clinical evaluation may help identify individuals who might benefit from increased surveillance and future treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00000173.

AB - Background: Individuals diagnosed as having mild cognitive impairment (MCI) have a high likelihood of progressing to dementia within 3 to 5 years, but not all individuals with MCI progress to dementia. Prognostic uncertainty suggests the need for additional measures to assist the clinician. Objective: To assess the added value of qualitative measures of medial temporal atrophy (MTA) to estimate the relative risk of progressing from MCI to dementia. Design: A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia. Setting: Memory assessment centers. Patients: A total of 190 individuals with MCI. Main Outcome Measures: Ratings of MTA performed using magnetic resonance images obtained at baseline. Log-rank tests and Cox proportional hazards ratios examining the significance of MTA estimates in predicting progression of MCI to dementia. Results: A mean MTA score greater than 2.0 was associated with a greater than 2-fold increased likelihood of progression to dementia during the observation period (hazards ratio, 2.30; 95% confidence interval, 1.09-4.92; P=.03) after controlling for age, education, sex, and baseline Mini-Mental State Examination score. Conclusions: Adjusted estimates of MTA were associated with significantly increased risk of developing dementia within 3 years, suggesting that obtaining a magnetic resonance image during the evaluation of MCI may offer additional independent information about the risk of progression to dementia. Given the relatively high prevalence of MCI in the general population, use of this method as part of routine clinical evaluation may help identify individuals who might benefit from increased surveillance and future treatment. Trial Registration: clinicaltrials.gov Identifier: NCT00000173.

UR - http://www.scopus.com/inward/record.url?scp=33846048774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846048774&partnerID=8YFLogxK

U2 - 10.1001/archneur.64.1.108

DO - 10.1001/archneur.64.1.108

M3 - Article

VL - 64

SP - 108

EP - 115

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 1

ER -